We focused on both alterations that have been discovered recently in at least one glioma subtype by high-throughput molecular analyses (ATRX, CIC, FUBP1) and on classic alterations (IDH, TP53, 1p/19q) that could be routinely detected in a molecular genetics laboratory. The gene discussed is IDH2; the disease is central nervous system cancer.